Dr. Hubert Chen Joins ADARx Pharmaceuticals as Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the appointment of Hubert C. Chen, M.D. as Chief Medical Officer.

“We are delighted to have Hubert join ADARx at such a pivotal moment in our company’s growth,” said Dr. Zhen Li, President and Chief Executive officer of ADARx. “Hubert’s track record and leadership, particularly in clinical development and regulatory negotiations, will be invaluable as we progress into the clinic.”

Dr. Chen brings to ADARx extensive clinical, scientific and managerial experience. He previously served as the Chief Medical Officer of Metacrine, a clinical-stage company focused on the treatment of liver and gastrointestinal diseases. Prior, Dr. Chen served as the Chief Scientific and Medical Officer of Pfenex, where he oversaw all aspects of research & development in multiple therapeutic areas, culminating in the approval of a teriparatide injectable in the US in 2019 and EU in 2020. Additional experiences include increasing roles and responsibilities at Aileron Therapeutics, Regulus Therapeutics, Amylin Pharmaceuticals and Amgen.

Dr. Chen obtained his M.D. from Columbia University. He trained in internal medicine at Massachusetts General Hospital, specialized in endocrinology at the University of California, San Francisco and conducted basic research at the Gladstone Institute of Cardiovascular Disease.

"I am thrilled to join ADARx at such an exciting and important juncture,” said Dr. Chen. “I believe ADARx has a versatile, industry-leading technology platform, which can rapidly advance RNA-based precision therapeutics from bench to clinical development and eventual commercialization. I look forward to joining the company’s mission, which is to bring about effective, safe and convenient treatment options for patients with serious unmet needs."

About ADARx

ADARx Pharmaceuticals, Inc., located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, and central nervous system diseases.

ADARx Contact
Roselle Corbaley
(877) 232-7974
ir@adarx.com